The groundbreaking success of Sildenafil undeniably reshaped the medication landscape, but placing funds in companies strongly reliant on generic versions presents a uncertain picture. Despite early earnings were significant, the cessation of patents and the appearance of discounted alternatives have weakened market share. Thus, a thorough assessme